# CONDOR

Source: https://nuclide.cc/trials/condor/  
Nuclide record `condor` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A PET scan using a PSMA tracer (piflufolastat F-18, brand Pylarify) was tested in men whose prostate cancer PSA had risen again but standard scans could not find where, to see how reliably it could locate the recurrence.

## Summary

CONDOR was a phase 3, prospective, multicentre, open-label, single-arm trial of 18F-DCFPyL (piflufolastat F-18, brand Pylarify) in men with biochemically recurrent prostate cancer and negative or equivocal conventional imaging (CT, MRI, bone scan, or fluciclovine/choline PET). It followed the earlier phase 2/3 OSPREY trial. The primary endpoint was correct localisation rate (CLR): positive predictive value plus a requirement that the PET-positive lesion anatomically co-localised with a composite standard of truth (histopathology, correlative imaging, or post-radiotherapy PSA response).

Of 208 men enrolled (median PSA 0.8 ng/mL), the CLR was 84.8-87.0% across three independent readers, comfortably exceeding the pre-specified threshold, and performance was maintained across all three standard-of-truth categories. 18F-DCFPyL detected at least one lesion in 59-66% of patients, and the scan changed the intended management plan in 63.9% of evaluable patients, most often a shift to targeted radiotherapy.

CONDOR, together with OSPREY, formed the basis of the May 2021 FDA approval of piflufolastat F-18 (Pylarify) for PSMA PET imaging in both initial high-risk staging and biochemical recurrence, one of the tracers that established PSMA PET as standard practice ahead of the confirmatory proPSMA trial.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Also known as: 18F-DCFPyL biochemical recurrence trial
- Tags: diagnostic trial; prostate cancer; biochemical recurrence
- Registry id: NCT03739684
- Phase: 3
- Setting: Men with biochemically recurrent prostate cancer after radical prostatectomy or radiotherapy, with negative or equivocal conventional imaging; a diagnostic (imaging) trial
- Sponsor: Progenics Pharmaceuticals
- Enrolled: 208
- Result: Correct localisation rate 84.8-87.0% across three readers, meeting the primary endpoint; 63.9% of patients had a change in intended management after the scan (Morris et al., Clinical Cancer Research 2021)
- Outcomes: Correct localisation rate vs composite standard of truth: 18F-DCFPyL (piflufolastat F-18) PET-CT 86%; Change in intended patient management: 18F-DCFPyL PET-CT 63.9%

## Sources

- Clinical Cancer Research 2021: CONDOR primary results (Morris et al.): https://pubmed.ncbi.nlm.nih.gov/33622706/
- ClinicalTrials.gov: NCT03739684: https://clinicaltrials.gov/study/NCT03739684

## Connected records

- drugs: [Piflufolastat F-18 / Pylarify TruVu](https://nuclide.cc/drugs/pylarify/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/)
- indications: [Biochemical recurrence of prostate cancer](https://nuclide.cc/indications/prostate-bcr/)
- trials: [OSPREY](https://nuclide.cc/trials/osprey/)
- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/)

---
JSON: https://nuclide.cc/api/v1/entities/condor.json